Potential of immunomodulatory host defense peptides as novel anti-infectives - PubMed (original) (raw)

Review

Potential of immunomodulatory host defense peptides as novel anti-infectives

Donna M Easton et al. Trends Biotechnol. 2009 Oct.

Abstract

A fundamentally new strategy for the treatment of infectious disease is the modulation of host immune responses to enhance clearance of infectious agents and reduce tissue damage due to inflammation. Antimicrobial host defense peptides have been investigated for their potential as a new class of antimicrobial drugs. Recently their immunomodulatory activities have begun to be appreciated. Modulation of innate immunity by synthetic variants of host defense peptides, called innate defense regulators (IDRs), is protective without direct antimicrobial action. We discuss the potential and current limitations in exploiting the immunomodulatory activity of IDRs as a novel anti-infective pathway. IDRs show significant promise and current research is uncovering mechanistic information that will aid in the future development of IDRs for clinical use.

PubMed Disclaimer

Figures

Figure 1

Design strategies for IDRs. Design and testing of IDRs are iterative processes. Initial candidate peptides are based on naturally occurring HDPs, designed using computational tools or randomly generated. These candidate peptides are tested in vitro and in vivo and computational analysis is used to select characteristics associated with function. New candidate peptides can then be designed using this structure–function relationship information and further testing reveals further information. Data from in vitro and in vivo testing also inform studies of the mechanism of action of IDRs and this information can feed back in to the bioinformatic and computational design approach. The structural diagram is LL-37 taken from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank.

Cited by

Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulation.
Thivierge K, Cotton S, Schaefer DA, Riggs MW, To J, Lund ME, Robinson MW, Dalton JP, Donnelly SM. Thivierge K, et al. PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2307. doi: 10.1371/journal.pntd.0002307. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23875042 Free PMC article.
Structure, dynamics, and antimicrobial and immune modulatory activities of human LL-23 and its single-residue variants mutated on the basis of homologous primate cathelicidins.
Wang G, Elliott M, Cogen AL, Ezell EL, Gallo RL, Hancock RE. Wang G, et al. Biochemistry. 2012 Jan 17;51(2):653-64. doi: 10.1021/bi2016266. Epub 2012 Jan 6. Biochemistry. 2012. PMID: 22185690 Free PMC article.
High-throughput discovery of broad-spectrum peptide antibiotics.
Rathinakumar R, Wimley WC. Rathinakumar R, et al. FASEB J. 2010 Sep;24(9):3232-8. doi: 10.1096/fj.10-157040. Epub 2010 Apr 21. FASEB J. 2010. PMID: 20410445 Free PMC article.
A Novel Class of Cationic and Non-Peptidic Small Molecules as Hits for the Development of Antimicrobial Agents.
Jiménez A, García P, de la Puente S, Madrona A, Camarasa MJ, Pérez-Pérez MJ, Quintela JC, García-Del Portillo F, San-Félix A. Jiménez A, et al. Molecules. 2018 Jun 22;23(7):1513. doi: 10.3390/molecules23071513. Molecules. 2018. PMID: 29932141 Free PMC article.
Inhibition of Pseudomonas aeruginosa biofilm formation and expression of virulence genes by selective epimerization in the peptide Esculentin-1a(1-21)NH2.
Casciaro B, Lin Q, Afonin S, Loffredo MR, de Turris V, Middel V, Ulrich AS, Di YP, Mangoni ML. Casciaro B, et al. FEBS J. 2019 Oct;286(19):3874-3891. doi: 10.1111/febs.14940. Epub 2019 Jun 13. FEBS J. 2019. PMID: 31144441 Free PMC article.

References

1. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat. Med. 2004;10:1177–1185. - PMC - PubMed
1. WHO (2008) World Health Statistics 2008, World Health Organisation Press
1. Weiss R.A., McMichael A.J. Social and environmental risk factors in the emergence of infectious diseases. Nat. Med. 2004;10:S70–76. - PMC - PubMed
1. Spellberg B. The epidemic of antibiotic resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;46:155–164. - PubMed
1. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 2003;9:269–277. - PubMed

Potential of immunomodulatory host defense peptides as novel anti-infectives - PubMed (original) (raw)